Insulet (NASDAQ:PODD) Price Target Lowered to $247.00 at Leerink Partners

Insulet (NASDAQ:PODD) had its price objective reduced by Leerink Partners from $360.00 to $247.00 in a research note released on Thursday morning,MarketScreener reports.

A number of other analysts have also recently weighed in on the company. Evercore lowered their price objective on Insulet from $340.00 to $240.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Citigroup decreased their price objective on Insulet from $230.00 to $175.00 in a report on Thursday. BTIG Research cut their price objective on shares of Insulet from $320.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday. Stifel Nicolaus reduced their price target on Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $325.00 price target on shares of Insulet in a report on Tuesday, April 14th. Eighteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $257.09.

Insulet Trading Up 6.0%

Shares of NASDAQ:PODD opened at $160.40 on Thursday. Insulet has a 12-month low of $148.30 and a 12-month high of $354.88. The business’s fifty day simple moving average is $211.22 and its 200-day simple moving average is $263.85. The company has a market capitalization of $11.11 billion, a PE ratio of 37.30, a P/E/G ratio of 0.89 and a beta of 1.20. The company has a current ratio of 2.49, a quick ratio of 2.15 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period last year, the business posted $1.02 EPS. The business’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts predict that Insulet will post 6.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the purchase, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC increased its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Insulet during the fourth quarter worth $26,000. Elyxium Wealth LLC purchased a new position in shares of Insulet during the fourth quarter worth $28,000. DV Equities LLC purchased a new position in shares of Insulet during the fourth quarter worth $28,000. Finally, MV Capital Management Inc. purchased a new position in shares of Insulet during the fourth quarter worth $29,000.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 beat and guidance raise — Insulet reported Q1 revenue of $761.7M (+33.9% YoY) and adjusted EPS $1.42, topping estimates; management raised FY2026 constant‑currency revenue growth to 21%–23% and reiterated margin expansion, which helped lift sentiment. Business Wire: Q1 Results
• Positive Sentiment: Omnipod international momentum — Management highlighted sharp international Omnipod revenue growth and continued geographic expansion (including new Middle East Omnipod 5 launches), supporting growth durability beyond the U.S. market. Reuters: Growth/Forecast
• Positive Sentiment: Profitability and insider buying — Adjusted operating margin expanded and EPS beat consensus; several insiders (including the CEO) bought shares recently, which can signal management confidence. QuiverQuant: Earnings analysis & insider activity
• Neutral Sentiment: Analyst ratings still mixed — Several firms reiterated buy/overweight stances even as they trimmed targets; median analyst targets remain well above current levels, leaving upside claims but greater dispersion in near‑term expectations. QuiverQuant: Analyst moves & targets
• Negative Sentiment: Widespread price‑target cuts — Multiple brokers lowered targets (Piper Sandler, BofA/JPMorgan/others), reflecting model resets after the print; that put near‑term pressure on sentiment despite the beat. MarketScreener: Piper Sandler target cut

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.